BioNTech SE is a German biotechnology company headquartered in Mainz, Germany. Alongside Pfizer, it developed a COVID-19 vaccine now approved by the U.S. Food and Drug Administration for emergency use. Investors can back the company by purchasing American Depositary Receipts (ADRs) on the Nasdaq under the ticker symbol BNTX.
Latest updates
Friday, December 11: The U.S. Food and Drug Administration cleared the Covid-19 vaccine developed by Pfizer and BioNTech for emergency use, with millions of doses expected to go out in the next few days.
Tuesday, December 8: Britain began vaccinations using the drug developed by Pfizer and BioNTech.
Wednesday, December 2: The UK becomes the first country to approve the Pfizer-BioNTech vaccine for emergency use, with vaccine distribution expected for the following week.
Tuesday, December 1: Advisors to the Center for Disease Control recommended that the first doses of any COVID-19 vaccine should be given to health-care workers and workers in nursing homes and other care facilities, according to news reports.
Wednesday, November 18: Pfizer releases final data from its Phase 3 study and amends the efficacy rate of its vaccine, stating its vaccine is 95% effective in preventing COVID-19.
Monday, November 9: Pfizer announces the two-dose vaccine it’s developing with BioNTech is over 90% effective in preventing COVID-19.
How to buy shares in BioNTech
Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
Open your brokerage account.Complete an application with your details.
Confirm your payment details.Fund your account.
Research the stock.Find the stock by name or ticker symbol – BNTX – and research it before deciding if it's a good investment for you.
Purchase now or later.Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
Check in on your investment.Optimize your portfolio by tracking your stock.
We evaluate stock trading platforms against a range of metrics that include fees, ease of use, available securities and advanced tools to meet specific investor needs. We encourage you to compare stock platforms to find one that's best for your particular budget and goals.
Our pick for building a portfolio. We chose SoFi for this category because it offers both commission-free stocks and a free robo-advisor. That means you can open an active investing account to pick and choose companies you want to invest in, and open a robo-advisor account to help you build a portfolio and manage how much risk you take on.
Our pick for beginners. We chose Robinhood for this category because it offers commission-free trading and is easy to use. You can search for stocks by company name, and the mobile app is clean and intuitive to use.
Our pick for active traders. We picked Interactive Brokers for this category because it offers advanced tools and low fees for active investors and pros. The simpler IBKR Lite platform is aimed at less-active investors, but all users older than 21 must meet a $20,000 liquid net worth requirement for a cash account.
On Nov. 9, Pfizer released a statement based on an early analysis of the two-dose COVID-19 vaccine it’s developing with BioNTech. The company says its vaccine is 95% effective in preventing COVID-19 in patients with no evidence of prior infection.
That said, the protection rate of the vaccine could change by the time its study ends. This is encouraging data — but it’s early data. And it hasn’t been peer-reviewed.
On December 2, the UK became the first country to officially approve the Pfizer-BioNTech COVID-19 vaccine for emergency use. The first round of vaccines is expected to roll out in the following weeks to front-line medical workers and residents of long-term care homes.
Pfizer is also preparing an application to the U.S. Food and Drug Administration (FDA) for emergency-use approval. Canadian Prime Minister Justin Trudeau has placed an order for 20 million doses of the vaccine, stating the vaccine will be deployed as soon as it’s approved by Health Canada.
In response to Pfizer’s announcement, the S&P 500 rose 2.8%, the Dow Jones Industrial Average surged by 1,092 points, Pfizer’s stock saw a 9% increase and BioNTech’s stock saw a 14% increase.
Pfizer expects to produce over 50 million doses in 2020 and up to 1.3 billion doses in 2021. A panel advising the Centers for Disease Control recommended December 1 that the first doses go to health-care workers and the staffs of nursing homes and care facilities.
How has coronavirus impacted BioNTech's share price?
Since the stock market crash in March caused by coronavirus, BioNTech's share price has had significant positive movement.
Its last close price was $188.28, which is 82.82% up on its pre-crash value of $32.35 and 572.43% up on the lowest point reached during the March crash when the shares fell as low as $28.00.
If you had bought $1,000 worth of BioNTech shares at the start of February 2020, those shares would have been worth $1.00 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $6.00.
BioNTech share price
Use our graph to track the performance of BNTX stocks over time.
Compare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy BioNTech stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
BioNTech price performance over time
Historical closes compared with the close of $188.28 from 2021-03-11
1 week (2021-04-30)
188.28
1 month (2021-04-07)
66.15%
3 months (2021-02-05)
60.14%
6 months (2020-11-06)
104.65%
1 year (2020-05-07)
281.75%
2 years (2019-05-03)
N/A
3 years (2018-05-03)
N/A
5 years (2016-05-03)
N/A
Is BioNTech under- or over-valued?
Valuing BioNTech stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of BioNTech's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
BioNTech's PEG ratio
BioNTech's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.1846. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into BioNTech's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
BioNTech financials
Revenue TTM
$482.3 million
Gross profit TTM
$-222,037,000
Return on assets TTM
-13.07%
Return on equity TTM
1.63%
Profit margin
3.15%
Book value
N/A
Market capitalisation
$46 billion
TTM: trailing 12 months
Shorting BioNTech shares
There are currently 4.7 million BioNTech shares held short by investors – that's known as BioNTech's "short interest". This figure is 0.3% down from 4.8 million last month.
There are a few different ways that this level of interest in shorting BioNTech shares can be evaluated.
BioNTech's "short interest ratio" (SIR)
BioNTech's "short interest ratio" (SIR) is the quantity of BioNTech shares currently shorted divided by the average quantity of BioNTech shares traded daily (recently around 1.9 million). BioNTech's SIR currently stands at 2.56. In other words for every 100,000 BioNTech shares traded daily on the market, roughly 2560 shares are currently held short.
However BioNTech's short interest can also be evaluated against the total number of BioNTech shares, or, against the total number of tradable BioNTech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioNTech's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 BioNTech shares in existence, roughly 20 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable BioNTech shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against BioNTech.
We're not expecting BioNTech to pay a dividend over the next 12 months.
BioNTech overview
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc. ; Sanofi S.
Jing Jun Ma is a tech and data expert with more than a decade of experience in digital marketing and programming. He wrangles data to make it useful for consumers facing a decision.
How likely would you be to recommend finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
Advertiser Disclosure
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.
